BMS Compound definition

BMS Compound means BMS’s proprietary anti-PD-1 monoclonal antibody known as Nivolumab.

BMS Compound is a molecule that is provided to Exelixis by BMS under a code name pursuant to Section 4.1 or 4.3, such that BMS does not disclose the identity or structure of such molecule to Exelixis. It is understood that "BMS Compounds" may include [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

BMS Compound means BMS’s proprietary anti-PD-1 monoclonal antibody known as Nivolumab and Opdivo®.

Examples of BMS Compound in a sentence

• The BMS Compound shall be Manufactured in accordance with Applicable Law (including GMP) and shall be of similar quality to the BMS Compound used by BMS for its other clinical trials of the BMS Compound.

• Such Stage I research shall include optimization of the delivery of such BMS Compound to a model system organism and analysis of any phenotype arising in said model system organism as a result of BMS Compound delivery.

• Following approval and allocation of sufficient FTE resources by the JMT, BMS may provide additional BMS Compound sets to Exelixis from time-to-time during the Research Term for use by Exelixis in the Mode of Action Program.

• Upon mutual agreement between the Parties, BMS may collaborate with Exelixis on Stage I, Stage II and Stage III activities with respect to a particular BMS Compound, wherein BMS may perform some of the Mode of Action Program work on such BMS Compound.

• BMS shall not reveal the identity or structure of any BMS Compound to Exelixis, but it may provide Exelixis with information concerning the putative function of an BMS Compound or other such information as may help Exelixis perform its duties under the Mode of Action Program (which information shall be treated as BMS Confidential Information).

More Definitions of BMS Compound

BMS Compound means a compound or product in the BMS Compound Collection, or any Analog thereof.

BMS Compound means nivolumab. For avoidance of doubt, BMS Compound shall not include any biosimilar version of nivolumab (i.e., that is not proprietary to BMS or its Affiliates).

BMS Compound means (a) any Compound that is provided by or on behalf of BMS to Exscientia for use in the Research Program, and (b) any Compound that is discovered, generated, created or conceived by Exscientia that is a derivative, fragment, modification, analog, homolog, salt, free acid/base, clathrate, chelate, conformer, congener, solvate, anhydride, hemi-hydrate, hydrate, ester, isomer, enantiomer, racemate, non-crystalline form, crystalline form, polymorphic form, prodrug, metabolite, isotopic or radiolabeled equivalent, conjugate, complex, or mixture of any Compound falling within the scope of clause (a).

BMS Compound means Nivolumab. [***]

BMS Compound means (individually and collectively, where applicable) (i) Nivolumab and/or (ii) the applicable Other BMS Therapeutic, in the case where the Combined Therapy Study includes an Other BMS Therapeutic as specified in the applicable Protocol for such Combined Therapy Study. Accordingly, as applied to any Combined Therapy Study that includes an Other BMS Therapeutic, in each provision of this Agreement where there is reference to ‘the BMS Compound’, such provision shall apply to Nivolumab and the applicable Other BMS Therapeutic, individually and collectively. For avoidance of doubt, the BMS Compound shall not include any biosimilar version of Nivolumab or of any Other BMS Therapeutic (i.e., that is not proprietary to BMS).

BMS Compound means: (a) those LXR Modulators or Dual LXR/FXR Modulators that are set forth in the Disclosure Letter and that are being contributed to the Collaboration by BMS as of [ * ]; (b) any LXR Modulators or Dual LXR/FXR Modulators that are contributed to the Collaboration by BMS [ * ] at [ * ] and subject to [ * ]; and (c) [ * ].

BMS Compound means each of BMS’s proprietary anti-PD-1 monoclonal antibody known as Nivolumab and BMS’s proprietary CTLA-4 monoclonal antibody known as Ipilimumab. In the event that any provision of this Agreement refers to the BMS Compound(s) or to Compound(s) of BMS or otherwise imposes an obligation on, or grants a right to, BMS in relation to such Compound(s), this provision will be read to relate to Nivolumab alone, to Ipilimumab alone or to both of them jointly, as is required in order to give full effect to such provision.